| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| S9083 |
Global fee urgent care centers |
97,915 |
84,867 |
$9.11M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
69,803 |
65,421 |
$6.01M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
36,699 |
34,331 |
$2.71M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
31,161 |
30,302 |
$2.20M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
83,762 |
74,563 |
$2.12M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
17,270 |
16,888 |
$1.67M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
65,245 |
62,210 |
$532K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
50,293 |
24,084 |
$411K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
50,721 |
45,453 |
$285K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
4,630 |
4,464 |
$108K |
| 99384 |
|
1,160 |
1,154 |
$40K |
| 99000 |
|
5,968 |
5,780 |
$33K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
601 |
582 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
408 |
331 |
$7K |
| 87807 |
|
1,818 |
1,747 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,055 |
895 |
$4K |
| 81002 |
|
1,065 |
1,032 |
$1K |
| 99072 |
|
5,510 |
5,102 |
$702.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,446 |
1,136 |
$334.00 |
| 73610 |
|
13 |
13 |
$270.27 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
1,955 |
1,899 |
$234.50 |
| 99401 |
|
277 |
272 |
$73.53 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
65 |
65 |
$71.12 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
509 |
491 |
$49.00 |
| 96136 |
|
202 |
184 |
$38.59 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
116 |
85 |
$18.00 |
| 96160 |
|
152 |
109 |
$9.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
138 |
134 |
$2.94 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
38 |
32 |
$0.55 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
2,054 |
1,552 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
28 |
28 |
$0.00 |
| 99201 |
|
19 |
18 |
$0.00 |
| 96127 |
|
1,911 |
1,540 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
2,062 |
1,640 |
$0.00 |